



Fasenra[®] (benralizumab) – New formulation approval

- On October 4, 2019, [AstraZeneca announced](#) the FDA approval of [Fasenra \(benralizumab\)](#) single-dose autoinjector, for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
 - Fasenra is not indicated for treatment of other eosinophilic conditions.
 - Fasenra is not indicated for the relief of acute bronchospasm or status asthmaticus.
- Fasenra autoinjector is intended for administration by patients/caregivers. Patients/caregivers may inject after proper training in subcutaneous (SC) injection technique and after the healthcare provider determines it is appropriate.
- Fasenra was previously approved as a single-dose prefilled syringe. However, the prefilled syringe requires administration by a healthcare provider.
- Warnings and precautions of Fasenra include hypersensitivity reactions, acute asthma symptoms or deteriorating disease, reduction of corticosteroid dosage, and parasitic (helminth) infection.
- The most common adverse reactions ($\geq 5\%$) with Fasenra use were headache and pharyngitis.
- The recommended dosage of Fasenra for severe asthma is 30 mg administered once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter by SC injection into the upper arm, thigh, or abdomen.
- AstraZeneca's launch plans for the single-dose autoinjector are pending. The new formulation will be available as a 30 mg/mL strength autoinjector (Fasenra Pen).



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.